About Linkage Biosciences
Linkage Biosciences is a molecular diagnostics company developing products that will dramatically improve and expedite complex genetic testing. Our initial focus is on diagnostic products for stem cell and solid organ transplantation where our proprietary technology will have an immediate impact. We have assembled an outstanding management team and scientific advisory board who are well known experts in their respective fields. Please stay tuned for further announcements.
Missing: Linkage Biosciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Linkage Biosciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Linkage Biosciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Linkage Biosciences is included in 4 Expert Collections, including Regenerative Medicine.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Latest Linkage Biosciences News
Sep 17, 2016
17.09.2016 – 11:31 San Francisco (ots/PRNewswire) - Linkage Biosciences, ein weltweit führendes Unternehmen im Bereich der Transplantationsdiagnostik, hat heute bekanntgegeben, daß es den Zuspruch für einen 4-Jahresvertrag zur Implementierung von LinkSeq Real-Time PCR HLA Typisierungsprodukten durch das britische NHS Blood and Transplant (NHSBT) erhalten hat. Die neue Gewebetypisierungsplattform, inklusive Real-Time PCR Geräten, wird in mehreren Labors des Landes installiert werden. Dr. Andrea Harmer, National Head of NHS Blood and Transplant H&I Services, sagte, "At NHS Blood and Transplant, we were looking for the best technology available for our rapid typing requirements. We developed a comprehensive matrix to evaluate multiple platforms and were extremely pleased with the results from Linkage Biosciences. The laboratory tests performed by our scientists showed the product to be simple to use, fast, and robust. " "Wir freuen uns über die Partnerschaft mit NHS Blood and Transplant und unterstützen eine schnelle Einführung der LinkSeq Gewebetypisierungstechnologie" sagte Zachary Antovich, Chief Executive Officer von Linkage Biosciences. "Die technologischen Vorteile von LinkSeq, dokumentiert durch die Daten während der Evaluierungsphase, haben klar die Überlegenheit unseres Angebots gezeigt. Die Entscheidung des UK NHS Blood and Transplant für unser Produkt ist das Ergebnis einer sorgfältigen Evaluierung verschiedener am Markt erhältlicher Produkte und wir nehmen an, daß andere Länder diese Ausschreibung als Orientierungshilfe für ihre eigene Entscheidung verwenden werden. " LinkSeq bietet eine deutliche Vereinfachung des Arbeitsablaufes zur Detektierung der Human Leukocyte Antigen (HLA) Gene, verbunden mit der Gewebekompatibilität für die Organtransplantation. Mit weniger als 10 Minuten Vorbereitungszeit und keinen weiteren manuellen Tätigkeiten, liefert LinkSeq in 90 Minuten eine komplette molekulargenetische Typisierung. Der einfache Arbeitsablauf verhindert post-amplification Kontaminationen und erlaubt schnelle Ergebnisse sowie hohe Produktivität im Labor. Seit der Einführung in 2011 wurde LinkSeq in über 120 Laboren auf 4 Kontinenten eingeführt. 2015 hat die Firma die Zulassung für Europa erhalten. Über NHS Blood and Transplant NHS Blood and Transplant ist eine gemeinsame Gesundheitsbehörde von England und Wales. Es ist für eine sichere und effiziente Versorgung mit Blut und damit verbundenen Services an das NHS in England verantwortlich. Es ist auch die Organspendeorganisation für das UK und ist verantwortlich für die Zuteilung passender Spenderorgane. Über Linkage Biosciences Linkage Biosciences ist ein molekulardiagnostisches Unternehmen, welches Produkte entwickelt und vermarktet, die zu einer deutlichen Verbessung und Beschleunigung komplexer genetischer Tests führen. LinkSeq ist die führende Technologie der Firma und deckt alle klassischen HLA Gene und über 13.000 Allele in einem einzigen Testvorgang ab. LinkSeq Technologie verwendet eine firmenintern entwickelte Testmethode inklusive Reagenzien und Software zusammen mit Standard Real-Time PCR Geräten zur Vereinfachung der Bestimmung komplexer genetischer Sequenzen. Linkage Biosciences hat 2015 die CE IVD Kennzeichnung sowie die ISO 13485 Akkreditierung erhalten. Die Zentrale der Firma ist in South San Francisco, California. Linkage Biosciences und LinkS?q sind Markenzeichen von Linkage Biosciences, Inc. Für mehr Informationen besuchen Sie bitte www.linkagebio.com Medienkontakte:Matthew Frome+1 415 346 5262 email@example.com Original-Content von: Linkage Biosciences, übermittelt durch news aktuell
Linkage Biosciences Frequently Asked Questions (FAQ)
When was Linkage Biosciences founded?
Linkage Biosciences was founded in 2004.
Where is Linkage Biosciences's headquarters?
Linkage Biosciences's headquarters is located at 890 Dubuque Avenue, South San Francisco.
What is Linkage Biosciences's latest funding round?
Linkage Biosciences's latest funding round is Acquired.
How much did Linkage Biosciences raise?
Linkage Biosciences raised a total of $7.1M.
Who are the investors of Linkage Biosciences?
Investors of Linkage Biosciences include Thermo Fisher Scientific, Big Sky Partners, Greenhouse Capital Partners and Fisher Capital Corp.
Who are Linkage Biosciences's competitors?
Competitors of Linkage Biosciences include Aviir, Predictive Biosciences, VitaPath Genetics, MicroPhage, Aureon Laboratories and 9 more.
Compare Linkage Biosciences to Competitors
JJET is committed to the development, production, and sales of products in the field of electrophysiology; the products mainly include a three-dimensional cardiac mapping system, multi-channel physiological recorder, cardiac electrophysiological stimulator, cardiac radiofrequency ablation device, cold saline perfusion pump, cardiac electrophysiological mapping catheter, cardiac radiofrequency ablation catheter, nerve radiofrequency treatment instrument. The company was founded in 1991 and is based in Chengdu, China.
Flex Biomedical is developing technologies to treat and diagnose orthopedic diseases. Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer, designed to treat osteoarthritis.
Immutell aims to develop, produce and market Cell Mediated Immune Response diagnostics to help combat diseases that are difficult to diagnose.
AllerQuest was established by a team including Emeritus Professor Charlotte Ressler, specifically to further develop and produce skin test reagents to safely and accurately identify patients who are at risk for potentially life threatening reactions to penicillin antibiotics. The firm has developed a GMP facility in Plainville to support production and sales of their first product Pre-Pen. (Graduated from incubator)
StageMark is a healthcare company that intends to provide an early identification and monitoring solution for inflammatory diseases such as lupus.
Rubicor Medical is a private medical device company located in Redwood City, California. Our proprietary biopsy technology (Ovation Breast Biopsy Device) is a dramatic improvement over current minimally invasive biopsy technologies. The Ovation system is comprised of a 14-gauge biopsy device capable of excising, capturing and extracting an intact 2.5 cm diameter tissue sample. Ovation is compatible with either ultrasound or stereotactic image guidance. Rubicor was co-founded by Dr. James Vetter and has been privately funded by a consortium of individual investors.James W. Vetter, M.D., CEO and Chairman of the Board, is a board certified interventional cardiologist.He is an Associate Professor of Clinical Medicine at Stanford University Hospital, where he iscurrently on Active Staff status as community faculty. Dr. Vetter is a graduate of the MedicalCollege of Wisconsin where he completed a residency in internal medicine and a fellowship incardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. John SimpsonM.D./PhD., at Sequoia Hospital, Redwood City, California. Dr. Vetter is a member of the Alpha OmegaAlpha Honor Society and the American College of Cardiologists. He has published six articles andseveral book chapters as well as over 35 abstracts. Dr. Vetter has held positions as a member of thePhysician Advisory Council and/or board member with a number of medical device companiesincluding Guidant, Lumend, Fox Hollow and CardioVasc. He is also a board member of MagellanSystems International, Inc.Dr. Vetter has extensive experience in working with new medical device concepts and designs,working with R&D engineers to develop working prototypes and clinically testing and refining thoseproducts. He was co-founder of Perclose and was involved with that company from inception toinitial public offering and eventual sale to Abbott Labs. He is a "hands on" clinician with access toresources and expertise needed to build a successful medical device and company. Dr. Vetter hashad a number of patents issued in his name as co-inventor.Ary Chernomorsky, V.P. of R&D since 2000 has over 23 years experience in the medical deviceindustry. Prior to joining Rubicor, Mr. Chernomorsky was employed by the Vascular Therapiesdivision of US Surgical Company (acquired by Tyco International), where he served as a Director ofR&D. Mr. Chernomorsky has been involved with various startup companies in the R&D Director andManager capacities including: PAS Inc. (acquired by USS), Advanced Surgical, Inc. (acquired byImagyn), Micro Therapeutics, Bausch and Lomb, Mentor Corporation and Dart Industries Inc. Aryholds an M.S. in Polymer Engineering from LIT and an M.S. in Biomedical Engineering from RutgersUniversity.Tony Difede, CPA, V.P. Finance holds a BSBA degree in Accounting from the University of Floridaand a M.S. in Taxation from Pace University. He has held management positions in tax and accountingwith Ernst & Young, KPMG and my CFO, Inc. His clients have included closely held start-upcompanies as well as large multinational public corporations. He is licensed in California and NewJersey. He has extensive experience in accounting for stock options and issues regarding closelyheld companies and their high net worth owners and investors.COMPANY INFOMANAGEMENTpage 12006 Company Overview (Continued)Breast care. Completely redefined.James W. Vetter, M.D., Founder and Chairman of the Board, is a board certified interventionalcardiologist. He is an Associate Professor of Clinical Medicine at Stanford University Hospital,where he is currently on Active Staff status as community faculty. Dr. Vetter is a graduate of theMedical College of Wisconsin where he completed a residency in internal medicine and a fellowshipin cardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. JohnSimpson M.D./PhD., at Sequoia Hospital, Redwood City, Cal
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.